Page last updated: 2024-09-04

perifosine and gefitinib

perifosine has been researched along with gefitinib in 5 studies

Compound Research Comparison

Studies
(perifosine)
Trials
(perifosine)
Recent Studies (post-2010)
(perifosine)
Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010) (gefitinib)
245311405,2315662,919

Protein Interaction Comparison

ProteinTaxonomyperifosine (IC50)gefitinib (IC50)
epidermal growth factor receptor isoform a precursorHomo sapiens (human)0.004
Cyclin-G-associated kinaseHomo sapiens (human)0.42
Multidrug resistance-associated protein 4Homo sapiens (human)4.6
Tyrosine-protein kinase ABL1Homo sapiens (human)1.2
Epidermal growth factor receptorHomo sapiens (human)0.3676
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.5699
Cytochrome P450 1A2Homo sapiens (human)0.151
Cytochrome P450 2E1Homo sapiens (human)0.46
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.7
Tyrosine-protein kinase HCKHomo sapiens (human)0.11
Quinolone resistance protein NorAStaphylococcus aureus9.7
Cytochrome P450 2C8Homo sapiens (human)0.151
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)1.1
Serine/threonine-protein kinase B-rafHomo sapiens (human)2
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)0.008
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.281
Cytochrome P450 2C19Homo sapiens (human)0.151
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)0.0073
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.9742
Ephrin type-B receptor 4Homo sapiens (human)1
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.001
Transcription factor p65Homo sapiens (human)0.055
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.086
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.29

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Breschi, MC; Danesi, R; Falasca, M; Fogli, S; Lapucci, A; Mey, V; Nesi, G; Rapposelli, S; Ricciardi, S; Sestito, S1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA1
Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L1

Reviews

1 review(s) available for perifosine and gefitinib

ArticleYear
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
    Radiographics : a review publication of the Radiological Society of North America, Inc, 2011, Volume: 31, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines

2011

Other Studies

4 other study(ies) available for perifosine and gefitinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer.
    ACS medicinal chemistry letters, 2013, Dec-12, Volume: 4, Issue:12

    Topics:

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    International journal of oncology, 2012, Volume: 41, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptors, LHRH; Signal Transduction; Tamoxifen; TOR Serine-Threonine Kinases

2012